Patents by Inventor Elliot Chaikof

Elliot Chaikof has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240092935
    Abstract: The present disclosure provides anti-Tn antibodies (e.g., BaGs6 and/or Remab6) having superior specificity for Tn antigen on cancer cells. Also provided herein, are nucleic acids, vectors, or vector sets that encode the anti-Tn antibody.
    Type: Application
    Filed: October 9, 2020
    Publication date: March 21, 2024
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Richard D. Cummings, Elliot Chaikof, Yasuyuki Matsumoto, Matthew R. Kudelka
  • Publication number: 20230278986
    Abstract: Provided are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, tautomers, isotopically labeled derivatives, polymorphs, and prodrugs thereof, wherein X1—X4, RX, RC, RB, n, and Ring A are as defined herein. The compounds may be aryl hydrocarbon receptor agonists or partial aryl hydrocarbon receptor agonists. Also provided are pharmaceutical compositions comprising a compound of Formula (I) and methods of using such compounds for treating diseases and conditions related to the activity of an aryl hydrocarbon receptor, such as, for example, inflammatory diseases, autoimmune diseases, metabolic disorders, and proliferative diseases.
    Type: Application
    Filed: March 9, 2023
    Publication date: September 7, 2023
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Elliot Chaikof, Lijun Sun
  • Patent number: 11634408
    Abstract: Provided are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, tautomers, isotopically labeled derivatives, polymorphs, and prodrugs thereof, wherein X1-X4, RX, RC, RB, n, and Ring A are as defined herein. The compounds may be aryl hydrocarbon receptor agonists or partial aryl hydrocarbon receptor agonists. Also provided are pharmaceutical compositions comprising a compound of Formula (I) and methods of using such compounds for treating diseases and conditions related to the activity of an aryl hydrocarbon receptor, such as, for example, inflammatory diseases, autoimmune diseases, metabolic disorders, and proliferative diseases.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: April 25, 2023
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Elliot Chaikof, Lijun Sun
  • Publication number: 20210147390
    Abstract: Provided are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, tautomers, isotopically labeled derivatives, polymorphs, and prodrugs thereof, wherein X1-X4, RX, RC, RB, n, and Ring A are as defined herein. The compounds may be aryl hydrocarbon receptor agonists or partial aryl hydrocarbon receptor agonists. Also provided are pharmaceutical compositions comprising a compound of Formula (I) and methods of using such compounds for treating diseases and conditions related to the activity of an aryl hydrocarbon receptor, such as, for example, inflammatory diseases, autoimmune diseases, metabolic disorders, and proliferative diseases.
    Type: Application
    Filed: April 5, 2019
    Publication date: May 20, 2021
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Elliot Chaikof, Lijun Sun
  • Publication number: 20190300577
    Abstract: This disclosure relates to selectin inhibitors, compositions, and methods related thereto. In certain embodiments, the disclosure relates to glycopeptides that contain one or more modified amino acids conjugated to a saccharide or polysaccharide. In certain embodiments, the disclosure relates to uses of the glycopeptides as anti-inflammatory, antithrombotic, or anti-metastatic agents.
    Type: Application
    Filed: March 13, 2019
    Publication date: October 3, 2019
    Applicants: Beth Israel Deaconess Medical Center, Inc., Emory University
    Inventors: Richard D. Cummings, Elliot Chaikof, Venkata R. Krishnamurthy, Mohammed Sardar
  • Publication number: 20150284477
    Abstract: Compositions, reagents, kits, and methods for the reversible, covalent conjugation of functional molecules to engineered surfaces, e.g., surfaces of biomedical devices or used in analytical assays or industrial catalysis, are provided. The compositions, reagents, kits, and methods provided herein allow for the attachment, release, and replacement of functional molecules to and from engineered surfaces in vitro, in situ, and in vivo. Implantable vascular grafts, stents, catheters, and other medical devices with immobilized thrombomodulin-coated surfaces are provided. These molecules can be released from the device surface and replaced with fresh thrombomodulin via systemic administration of the respective reactants and without the need to remove the device.
    Type: Application
    Filed: October 30, 2013
    Publication date: October 8, 2015
    Inventors: Elliot Chaikof, Zheng Qu, Carolyn Haller, David R. Liu, Brent M. Dorr
  • Publication number: 20140193477
    Abstract: This disclosure relates to materials fabricated from collagen and uses relates thereto. Typically, layers of collagen are stretched during a curing period and optionally coated or impregnated with an elastin like protein. In certain embodiments, these materials can be used in tissue repair or arranged into cylinders and utilized as a prosthetic vascular graft.
    Type: Application
    Filed: October 11, 2013
    Publication date: July 10, 2014
    Applicants: Emory University, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Elliot Chaikof, Jeffrey Caves, Vivek Ashok Kumar, Adam W. Martinez
  • Publication number: 20060002903
    Abstract: The invention comprises anti-inflammatory conformal barriers with controllable permeability properties that can be applied to living cells prior to transplant, and methods for coating living cells with conformal barriers. The coatings comprise polymer layers deposited on a cell surface by layer-by-layer polymer assembly, wherein each layer contains a positive and a negative polymer pair. The barriers can be actively anti-inflammatory through incorporation of anticoagulant and/or anti-inflammatory agents into the barrier.
    Type: Application
    Filed: March 28, 2005
    Publication date: January 5, 2006
    Inventors: Elliot Chaikof, Wanxing Cui, Zhifei Dai
  • Publication number: 20050180945
    Abstract: Polymeric molecules including glycopolymers useful for biomolecular recognition processes are provided comprising anchoring groups by which they can be immobilized onto surfaces. These molecules are easily synthesized. They are broadly described as molecules comprising a polymer backbone with pendent multivalent groups attached to the polymer backbone and an anchoring group attached to the polymer backbone for covalently or noncovalently attaching the molecule to a surface or another molecule. Such polymeric molecules can be attached to other molecules or surfaces to provide a wide range of bioactive materials. In addition, this invention provides sulfated glycopolymers which are useful for reducing blood coagulation, stimulating growth factors to bind to their receptors, stimulating cell proliferation and preventing degradation of soluble growth factors under conditions of low pH, heat, and proteolytic enzymes.
    Type: Application
    Filed: May 21, 2003
    Publication date: August 18, 2005
    Inventors: Elliot Chaikof, Xue-Long Sun
  • Publication number: 20040063200
    Abstract: A biocompatible biological component is provided comprising a membrane-mimetic surface film covering a substrate. Suitable substrates include hydrated substrates, e.g. hydrogels which may contain drugs for delivery to a patient through the membrane-mimetic film, or may be made up of cells, such as islet cells, for transplantation. The surface may present exposed bioactive molecules or moieties for binding to target molecules in vivo, for modulating host response when implanted into a patient (e.g. the surface may be antithrombogenic or antiinflammatory) and the surface may have pores of selected sizes to facilitate transport of substances therethrough. An optional hydrophilic cushion or spacer between the substrate and the membrane-mimetic surface allows transmembrane proteins to extend from the surface through the hydrophilic cushion, mimicking the structure of naturally-occurring cells.
    Type: Application
    Filed: July 22, 2003
    Publication date: April 1, 2004
    Inventors: Elliot Chaikof, June Feng, Janine M. Orban, Hongbo Liu, Xue Long Sun, Keith M. Faucher